DTI for Injection

DTI for Injection Special Precautions

dacarbazine

Manufacturer:

Korea United Pharm [KR]

Distributor:

Masu
Full Prescribing Info
Special Precautions
Bone marrow suppression: Bone marrow suppression is the most common toxicity; leukopenia and thrombocytopenia may be severe; may result in treatment delays or discontinuation; anemia may also occur. Monitor CBC with differential. The onset for leukopenia is approximately 14 days (range: 10 - 30 days) and the duration is approximately 1 - 3 weeks. The onset for thrombocytopenia is approximately 18 days (range: 12 - 30 days) and the duration is approximately 1-3 weeks.
Hepatic effects: Hepatic necrosis has been reported. Hepatotoxicity may be accompanied with hepatic vein thrombosis and hepatocellular necrosis; may be fatal. Hepatotoxicity usually occurs with combination chemotherapy, but may occur with dacarbazine alone.
Gastrointestinal toxicity: Dacarbazine is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting.
Extravasation: Dacarbazine is an irritant; local reactions may occur, extravasation may result in tissue damage and severe pain.
Hypersensitivity reactions: May occur following dacarbazine administration.
Renal function impairment: Use with caution in patients with renal impairment; half-life is increased, monitor for toxicity and consider dosage reduction.
Hepatic Function impairment: Use with caution in patients with hepatic impairment; half-life is increased, monitor for toxicity and consider dosage reduction.
It is recommended that dacarbazine be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. The drug can produce severe, possibly fatal, hematologic or hepatic toxicity and severe GI reactions, and should be administered to patients who are preferably hospitalized and receive frequent determinations of hematopoetic function. In the treatment of each patient, the clinician must carefully weigh the possibility of achieving therapeutic benefits against the risks of toxicity.
If extravasation occurs, tissue damage and severe pain may occur. Care should be taken to avoid contact with the skin and eyes when reconstituting or administering dacarbazine. Hepatotoxic drugs and alcohol should be avoided during chemotherapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in